In the most extensive test so far of its capability to treat autism, the controversial drug secretin has failed to help children with the neurological disorder.
On Jan. 5, Repligen of Waltham, Mass., the biotech company seeking to develop secretin for use against autism, announced the disappointing results of its latest trial, which involved 132 children.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.